Physician profile
Danielle Doll
NPI 1568811560
$2,746.80
in general payments reported to CMS, 2019-2025
20 companies · $2,022 in 2025
The $2,022 reported for 2025 was more than what 94% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $209 · 2022: $288 · 2023: $58.90 · 2024: $169 · 2025: $2,022.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,182 · Food and Beverage: $1,068.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,182.02 |
| Food and Beverage | $1,067.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $1,873.84 | 2022-2025 | Inspire |
| Novartis Pharmaceuticals Corporation | $146.22 | 2021-2023 | |
| Boston Scientific Corporation | $131.00 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $97.79 | 2021-2025 | Tezspire, Breztri |
| Glaxosmithkline, LLC. | $71.11 | 2025 | Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $67.49 | 2023-2025 | Glassia |
| Amgen INC. | $54.63 | 2021-2025 | Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.27 | 2025 | Ofev |
| Regeneron Healthcare Solutions, INC. | $33.91 | 2024-2025 | Dupixent |
| Mylan Specialty L.P. | $33.64 | 2024 | Yupelri |
| Baxter Healthcare | $26.94 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $25.35 | 2021-2022 | |
| Philips North America LLC | $23.65 | 2025 | Vest Therapy Und |
| Phathom Pharmaceuticals, INC. | $20.20 | 2024 | Voquezna |
| Merck Sharp & Dohme LLC | $20.06 | 2025 | Winrevair |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $17.64 | 2025 | Prolastin-C Liquid |
| Abbott Laboratories | $17.20 | 2021 | |
| Inogen, INC. | $15.62 | 2024 | |
| Vifor Pharma, INC. | $14.50 | 2025 | Zemaira |
| Kiniksa Pharmaceuticals, Ltd. | $11.74 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Doll listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.